# Abstracts and Presentations

## 2023


## 2022

5. Rodig NM, Pizzo HP, Levy-Erez D, Richardson T, Somers MJG. Clinical Costs Associated with Induction Therapy for Pediatric Kidney Transplantation a NAPRTCS and PHIS Collaborative Study. American Transplant Congress 2022


## 2021


# Abstracts and Presentations

## 2018


## 2017


## 2011


## 2009


## 2008


Abstracts and Presentations


42. Dharnidharka VR, Martz KL, Stablein DM. IL-2R antibody induction is not associated with higher PTLD incidence: a report of the NAPRTCS. Oral presentation, IPTA, Cancun, Mexico, March 2007.


44. Dharnidharka VR, Martz KL, Stablein DM. Sirolimus use at day 30 is associated with higher risk of post-transplant lymphoproliferative disease (PTLD) in children post-kidney transplant. Oral presentation, IPTA, Cancun, Mexico, March 2007.


Abstracts and Presentations


57. Richards C. NAPRTCS—Who are We and What Do We Do? Poster presentation, ANNA 36th Annual Symposium. Las Vegas, Nevada, April 2005


68. Warady BA, Zobrist H, Zu Z. Sodium Ferric Gluconate Complex (SFGC) Therapy in children receiving hemodialysis: a
Abstracts and Presentations


82. Tejani A, Stablein DM, Ho PL. Calculated creatinine clearance (CCC) as the most promising candidate surrogate end point for clinical trials. Presented, ATC. Washington, DC, 2002.


Abstracts and Presentations


103. Baum MA, Stablein D, Panzarino V, Tejani A, Harmon WE. Graft loss due to recurrence eliminates the graft survival advantage of living donor (LD) over Cadaveric (CD) renal transplants (Tx) in children with focal segmental glomerulosclerosis (FSGS): A
Abstracts and Presentations


Abstracts and Presentations


